Chemistry:Ornidazole

From HandWiki
Short description: Chemical compound
Ornidazole
Ornidazole.svg
Clinical data
Trade namesXynor
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Pharmacokinetic data
MetabolismVia liver[1]:1356
Elimination half-life12-13 hours[1]:1356
ExcretionUrine (63%) and Feces (22%)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC7H10ClN3O3
Molar mass219.63 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Ornidazole is an antibiotic used to treat protozoan infections.[1]:1368 A synthetic nitroimidazole, it is commercially obtained from an acid-catalyzed reaction between 2-methyl-5-nitroimidazole and epichlorohydrin.[2]

Antimicrobial spectrum is similar to that of metronidazole and is more well tolerated;[1]:1368 however there are concerns of lower relative efficacy.[3]

It was first introduced for treating trichomoniasis before being recognized for its broad anti-protozoan and anti-anaerobic-bacterial capacities.[4]:1261 has also been investigated for use in Crohn's disease after bowel resection.[5]

References

  1. 1.0 1.1 1.2 1.3 "157 - Antiparasitic Agents". Infectious Diseases (Fourth ed.). Elsevier. 2017-01-01. pp. 1345–1372.e2. doi:10.1016/B978-0-7020-6285-8.00157-X. ISBN 978-0-7020-6285-8. http://www.sciencedirect.com/science/article/pii/B978070206285800157X. 
  2. "Chapter 17 - Nitroheterocycles". Pharmacochemistry Library. Approaches to Design and Synthesis of Antiparasitic Drugs. 25. Elsevier. January 1997. pp. 428. doi:10.1016/S0165-7208(97)80039-6. ISBN 9780444894762. 
  3. "28 - Metronidazole". Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth ed.). Content Repository Only!. January 2015. pp. 356. ISBN 978-1-4557-4801-3. 
  4. "147 - Nitroimidazoles, Metronidazole, Ornidazole and Tinidazole; and Fidaxomicin", Infectious Diseases (Fourth ed.), Elsevier, January 2017, pp. 1261–1263.e1, ISBN 978-0-7020-6285-8 
  5. "Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial". Gastroenterology 128 (4): 856–861. April 2005. doi:10.1053/j.gastro.2005.01.010. PMID 15825069.